Effect of Multidisciplinary Dyslipidemia Educational Program on Adherence to Guidelines Directed Medical Therapy in Saudi Arabia

被引:3
作者
AlAyoubi, Fakhr [1 ]
Hayajneh, Ahmad [2 ]
AlAyoubi, Samha [3 ]
Shaer, Fayez El [4 ,5 ]
机构
[1] King Saud Univ, King Saud Univ Med City, Dept Clin Pharm Serv, Riyadh, Saudi Arabia
[2] King Saud Univ, King Fahad Cardiac Ctr, Nursing Dept, Riyadh, Saudi Arabia
[3] King Saud Univ, King Fahad Cardiac Ctr, Cardiac Dept, Basic Sci Unit, Riyadh, Saudi Arabia
[4] King Saud Univ, King Fahad Cardiac Ctr, Cardiac Sci Dept, Riyadh, Saudi Arabia
[5] Natl Heart Inst, Cairo, Egypt
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES | 2021年 / 10卷 / 02期
关键词
Hyperlipidemia; Guidelines; Statin products; Saudi Arabia; Adherence; Education program; CARDIOVASCULAR-DISEASE; ATORVASTATIN; ASSOCIATION; CHOLESTEROL; MORTALITY; STATINS; TRIALS;
D O I
10.51847/Ib4osQuWE6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A prospective cohort study was conducted. The practice in three clinics, cardiology, primary care, and endocrine, was assessed by data collection including demographic information, lipid profile (HDL, triglyceride, LDL, total cholesterol), and lipid-lowering drugs. All consecutive patients with hyperlipidemia were included. Extensive educational sessions have been implemented at the beginning of the study. Morisky score was assessed at the initial visit and months 3 and 9 to assess the medication adherence. 401 patients were included with a mean age of 60 +/- 13 years, 62 % were males. Evaluation of the prescription pattern of lipid-lowering drugs in outpatient pharmacy revealed 40 % of the hyperlipidemic patients were prescribed lipid-lowering drugs with only 15% was on proper dosing. Rosuvastatin was prescribed more in PCC (60%) while Atorvastatin was more in Cardiology (80%). Initially, the research team conducted a workshop with a campaign to educate the health care practitioners with the guidelines directed to medical therapy. Morisky score calculation was carried out at the beginning, and months 3 and 9. Morisky score was used to evaluate therapy adherence together with knowledge and motivation level. Morisky score initially was above 2 (low adherence) in 43% of the patients and 2 or less (moderate to high adherence) in 57%. Morisky score (above 2) was decreased to 29% from at the first visit (month 3) to 12 % in the last visit (month 9), which reflect on the effectiveness of the extensive education program which was given by the research teams at the beginning of the study.
引用
收藏
页码:35 / 41
页数:7
相关论文
共 24 条
  • [1] Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future
    Akunne, Onyinye Onyeka
    Godman, Brian
    Adedapo, Aduragbenro Deborah
    Truter, Ilse
    Fadare, Joseph
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2016, 5 (03) : 281 - 288
  • [2] Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalities in the Setting of Chronic Statin Treatment
    Al Sifri, Saud N.
    Almahmeed, Wael
    Azar, Sami
    Okkeh, Osama
    Bramlage, Peter
    Juenger, Claus
    Halawa, Islam
    Ambegaonkar, Baishali
    Wajih, Sameh
    Brudi, Philippe
    [J]. PLOS ONE, 2014, 9 (01):
  • [3] Improvement initiative in LDL-C management in Saudi Arabia: A call to action
    Alasnag, Mirvat
    Awan, Zuhier
    Al Ghamdi, Ahmed
    Al Modaimeigh, Hind
    Al Shemiri, Mostafa
    [J]. IJC HEART & VASCULATURE, 2020, 31
  • [4] Arbaeen AM, 2020, INT J PHARM PHYTOPHA, V10, P130
  • [5] Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
    Boren, Jan
    Chapman, M. John
    Krauss, Ronald M.
    Packard, Chris J.
    Bentzon, Jacob F.
    Binder, Christoph J.
    Daemen, Mat J.
    Demer, Linda L.
    Hegele, Robert A.
    Nicholls, Stephen J.
    Nordestgaard, Brge G.
    Watts, Gerald F.
    Bruckert, Eric
    Fazio, Sergio
    Ference, Brian A.
    Graham, Ian
    Horton, Jay D.
    Landmesser, Ulf
    Laufs, Ulrich
    Masana, Luis
    Pasterkamp, Gerard
    Raal, Frederick J.
    Ray, Kausik K.
    Schunkert, Heribert
    Taskinen, Marja-Riitta
    van de Sluis, Bart
    Wiklund, Olov
    Tokgozoglu, Lale
    Catapano, Alberico L.
    Ginsberg, Henry N.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (24) : 2313 - +
  • [6] Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
  • [7] 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations
    Genest, Jacques
    McPherson, Ruth
    Frohlich, Jiri
    Anderson, Todd
    Campbell, Norm
    Carpentier, Andre
    Couture, Patrick
    Dufour, Robert
    Fodor, George
    Francis, Gordon A.
    Grover, Steven
    Gupta, Milan
    Hegele, Robert A.
    Lau, David C.
    Leiter, Lawrence
    Lewis, Gary F.
    Lonn, Eva
    Mancini, G. B. John
    Ng, Dominic
    Pearson, Glen J.
    Sniderman, Allan
    Stone, James A.
    Ur, Ehud
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2009, 25 (10) : 567 - 579
  • [8] Obesity and dyslipidemia
    Howard, BV
    Ruotolo, G
    Robbins, DC
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2003, 32 (04) : 855 - +
  • [9] Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
    Jones, PH
    Davidson, MH
    Stein, EA
    Bays, HE
    McKenney, JM
    Miller, E
    Cain, VA
    Blasetto, JW
    STELLAR Study Grp
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (02) : 152 - 160
  • [10] A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
    Kennedy-Martin, Tessa
    Curtis, Sarah
    Faries, Douglas
    Robinson, Susan
    Johnston, Joseph
    [J]. TRIALS, 2015, 16